» Articles » PMID: 31443240

NF-κB Signaling in Ovarian Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2019 Aug 25
PMID 31443240
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

The NF-κB signaling pathway is a master and commander in ovarian cancer (OC) that promotes chemoresistance, cancer stem cell maintenance, metastasis and immune evasion. Many signaling pathways are dysregulated in OC and can activate NF-κB signaling through canonical or non-canonical pathways which have both overlapping and distinct roles in tumor progression. The activation of canonical NF-κB signaling has been well established for anti-apoptotic and immunomodulatory functions in response to the tumor microenvironment and the non-canonical pathway in cancer stem cell maintenance and tumor re-initiation. NF-κB activity in OC cells helps to create an immune-evasive environment and to attract infiltrating immune cells with tumor-promoting phenotypes, which in turn, drive constitutive NF-κB activation in OC cells to promote cell survival and metastasis. For these reasons, NF-κB is an attractive target in OC, but current strategies are limited and broad inhibition of this major signaling pathway in normal physiological and immunological functions may produce unwanted side effects. There are some promising pre-clinical outcomes from developing research to target and inhibit NF-κB only in the tumor-reinitiating cancer cell population of OC and concurrently activate canonical NF-κB signaling in immune cells to promote anti-tumor immunity.

Citing Articles

Advanced Therapeutic Approaches for Metastatic Ovarian Cancer.

Choe S, Jeon M, Yoon H Cancers (Basel). 2025; 17(5).

PMID: 40075635 PMC: 11898553. DOI: 10.3390/cancers17050788.


Mebendazole Exerts Anticancer Activity in Ovarian Cancer Cell Lines via Novel Girdin-Mediated AKT/IKKα/β/NF-κB Signaling Axis.

Gupta R, Roy D, Ghosh A, Begum Y, Ghosh D, Swarnakar S Cells. 2025; 14(2).

PMID: 39851541 PMC: 11763501. DOI: 10.3390/cells14020113.


Interleukin-6 Modulation in Ovarian Cancer Necessitates a Targeted Strategy: From the Approved to Emerging Therapies.

Amer H, Kampan N, Itsiopoulos C, Flanagan K, Scott C, Kartikasari A Cancers (Basel). 2025; 16(24.

PMID: 39766086 PMC: 11674514. DOI: 10.3390/cancers16244187.


The NF-κB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancer.

Kim K, Khazan N, McDowell J, Snyder C, Miller J, Singh R PLoS One. 2024; 19(12):e0314564.

PMID: 39621651 PMC: 11611113. DOI: 10.1371/journal.pone.0314564.


ANKRD1 Promotes Breast Cancer Metastasis by Activating NF-B-MAGE-A6 Pathway.

Diskul-Na-Ayudthaya P, Bae S, Bae Y, Van N, Kim W, Ryu S Cancers (Basel). 2024; 16(19).

PMID: 39409926 PMC: 11476229. DOI: 10.3390/cancers16193306.


References
1.
Huang S, Robinson J, Deguzman A, Bucana C, Fidler I . Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 2000; 60(19):5334-9. View

2.
Hagemann T, Wilson J, Kulbe H, Li N, Leinster D, Charles K . Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol. 2005; 175(2):1197-205. DOI: 10.4049/jimmunol.175.2.1197. View

3.
Campbell K, Witty J, Rocha S, Perkins N . Cisplatin mimics ARF tumor suppressor regulation of RelA (p65) nuclear factor-kappaB transactivation. Cancer Res. 2006; 66(2):929-35. DOI: 10.1158/0008-5472.CAN-05-2234. View

4.
Hagemann T, Wilson J, Burke F, Kulbe H, Li N, Pluddemann A . Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol. 2006; 176(8):5023-32. DOI: 10.4049/jimmunol.176.8.5023. View

5.
Zhang Z, Ma J, Li N, Sun N, Wang C . Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer. Ann Thorac Surg. 2006; 82(1):243-8. DOI: 10.1016/j.athoracsur.2006.01.049. View